at induce tumor formation have remained unclear. In a study appearing online on June 8 in advance of print publication in the July issue of the Journal of Clinical Investigation, Chu-Xia Deng and colleagues from the NIH, generated a line of mice that develop CC by specifically disrupting expression of the tumor suppressor genes SMAD4 and PTEN in the livers of these mice. Tumors formed in the bile ducts of these animals by 47 months of age. The authors show that SMAD4 and PTEN regulate each others' activity in order to balance their expression and repress CC formation. The authors also examined human CC specimens and found that PTEN was inactivated in the majority of cases, and SMAD4 expression was lost in about half of the tumors examined. The results of this study help us understand the relationship between SMAD4 and PTEN and extend our understanding of CC formation.
TITLE: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten mice
AUTHOR CONTACT:
Chu-Xia Deng
National Institutes of Health, Bethesda, Maryland, USA.
Phone: (301) 402-7225; Fax: (301) 480-1135; E-mail: chuxiad@bdg10.niddk.nih.gov.
View the PDF of this article at: https://www.the-jci.org/article.php?id=27282
IMMUNOLOGY
T cell activity during the immune response: what regulates the regulators?
Regulatory T cells (Tregs) are a specialized subpopulation of T cells that act to suppress activation of the immune system and in doing so help prevent aggressive immune responses against our own tissues. However little is known about how Tregs themselves are regulated. In a study appearing online on June 8 in advance of print publication in the July issue of the Journal of Clinical Investigation, Irun R. Cohen and colleagues from the Weizmann Institute of Science in Rehovot, Israel, repo
'"/>
Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
8-Jun-2006
Page: 1 2 3 4 5 Related medicine news :1.
International symposium on fruit, vegetables headed for Houston2.
Stevens Roundtable: Health, Technology & Society, July 113.
FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma4.
Once-fatal metabolic disorders treatable, says Stanford/Packard researcher5.
Clinical review -- A psychological approach to the management of irritable bowel syndrome6.
JCI table of contents -- May 17, 20077.
JCI table of contents: May 10, 20078.
New treatments needed for irritable bowel syndrome9.
JCI table of contents: May 1, 200710.
Americans still not eating enough fruits and vegetables, according to 2 recent studies11.
Slow-release morphine reduces level of intractable cough